Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-100
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
mTOR/PLK1
Cancer name
Epithelial Ovarian Cancer
Cancer site
Ovary
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Tissue resource
human ovary cancer cell lines SKOV3
human ovary cancer cisplatin-resistant cell lines SKOV/DDP
Experiment
qRT-PCR,Western blot
Institute
Cancer Research Institute of Southern Medical University
Qingdao University Medical College Affiliated Hospital
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.